HomeCompareSBMFF vs SBUX

SBMFF vs SBUX: Dividend Comparison 2026

SBMFF yields 1.32% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $138.3K in total portfolio value
10 years
SBMFF
SBMFF
● Live price
1.32%
Share price
$0.76
Annual div
$0.01
5Y div CAGR
27.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.8K
Annual income
$2,017.55
Full SBMFF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — SBMFF vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSBMFFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SBMFF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SBMFF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SBMFF
Annual income on $10K today (after 15% tax)
$111.99/yr
After 10yr DRIP, annual income (after tax)
$1,714.92/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $58,751.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SBMFF + SBUX for your $10,000?

SBMFF: 50%SBUX: 50%
100% SBUX50/50100% SBMFF
Portfolio after 10yr
$97.9K
Annual income
$36,577.01/yr
Blended yield
37.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

SBMFF
No analyst data
Altman Z
3.2
Piotroski
7/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SBMFF buys
0
SBUX buys
0
No recent congressional trades found for SBMFF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSBMFFSBUX
Forward yield1.32%2.84%
Annual dividend / share$0.01$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR27.4%48.3%
Portfolio after 10y$28.8K$167.0K
Annual income after 10y$2,017.55$71,136.45
Total dividends collected$7.6K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: SBMFF vs SBUX ($10,000, DRIP)

YearSBMFF PortfolioSBMFF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$10,868$167.85$11,121$420.68$253.00SBUX
2$11,846$217.20$12,548$648.40$702.00SBUX
3$12,957$281.88$14,440$1,013.98$1.5KSBUX
4$14,231$367.10$17,068$1,617.30$2.8KSBUX
5$15,707$480.07$20,912$2,649.52$5.2KSBUX
6$17,438$630.89$26,875$4,499.29$9.4KSBUX
7$19,492$833.93$36,771$8,014.12$17.3KSBUX
8$21,967$1,109.91$54,542$15,197.11$32.6KSBUX
9$24,993$1,489.27$89,602$31,242.49$64.6KSBUX
10$28,761$2,017.55$167,011$71,136.45$138.3KSBUX

SBMFF vs SBUX: Complete Analysis 2026

SBMFFStock

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Full SBMFF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this SBMFF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SBMFF vs SCHDSBMFF vs JEPISBMFF vs OSBMFF vs KOSBMFF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.